Adalimumab biosimilar (Synermore Biologics)

阿达木单抗生物类似药（兴盟生物）

Report date: 2023/07/17 20:00:21

Base Information

Drug NameAdalimumab biosimilar (Synermore Biologics)
Drug Alias NameRecombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (Synermore Biologics)阿达木单抗生物仿制药（兴盟生物）重组抗肿瘤坏死因子-α全人源单抗（兴盟生物）重组全人抗肿瘤坏死因子α单抗（兴盟生物）重组抗TNFa全人单抗（兴盟生物） +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesLonn Ryonn Pharma LtdSynermore Biologics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSynermore Biologics (Suzhou) Co LtdLonn Ryonn Pharma Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeL04AB04
Related LinksN/A